Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics Inc (NQ: KYMR )

32.11 -0.05 (-0.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kymera Therapeutics Inc

< Previous 1 2 3 4 Next >
These Biotech Stocks Are the Nasdaq's Big Wednesday Winners
Business wins are shining the spotlight on these two companies. 
Via The Motley Fool
Dear DS Stock Fans, Mark Your Calendars for Dec. 23
Drive Shack (DS) stock is falling hard on Wednesday after the company warned investors of it delisting shares this month. 
Via InvestorPlace
Why Is SOFI Stock Up 7% Today?
SoFi Technologies (SOFI) stock is climbing higher on Wednesday after the company's CEO bought over 1 million more shares. 
Via InvestorPlace
Dear CRKN Stock Fans, Mark Your Calendars for Dec. 22
Crown Electrokinetics (CRKN) stock is on the move Wednesday as investors prepare for the company's upcoming shareholder meeting. 
Via InvestorPlace
Why Is Kymera Therapeutics (KYMR) Stock Up 20% Today?
KYMR stock traders are bidding up the share price today as Kymera Therapeutics teams up to take a skin condition treatment to the next phase. 
Via InvestorPlace
REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Kymera Therapeutics
Via Benzinga
Looking Into Kymera Therapeutics's Return On Capital Employed
Via Benzinga
Where Kymera Therapeutics Stands With Analysts
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial
Via Benzinga
US Stocks Higher Ahead Of Fed Decision
U.S. stocks traded higher this morning, with the Dow Jones gaining over 80 points on Wednesday 
Via Benzinga
Why Small Biotech Kymera Just Snagged Sanofi's Interest And Surged 28%
The company is working on protein degradation in cancer and inflammatory diseases. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
5 Analysts Have This to Say About Kymera Therapeutics
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
5 Analysts Have This to Say About Kymera Therapeutics
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Recap: Kymera Therapeutics Q3 Earnings
Kymera Therapeutics (NASDAQ:KYMR) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
Via Benzinga
5 Analysts Have This to Say About Kymera Therapeutics
  Within the last quarter, Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Via Benzinga
Kymera Gets Orphan Drug Status For Rare Blood Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics’ (NASDAQ: KYMR) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL). 
Via Benzinga
Looking Into Kymera Therapeutics's Return On Capital Employed
Kymera Therapeutics (NASDAQ:KYMR) brought in sales totaling $11.51 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 9.74%, resulting in a loss of $40.26... 
Via Benzinga
Where Kymera Therapeutics Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Kymera Therapeutics (NASDAQ:KYMR) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Insiders Buying Ecolab, Kymera Therapeutics And This Consumer Cyclical Stock
Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Kymera Therapeutics Stock Scores Rising Relative Price Strength
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
Kymera Therapeutics: Q2 Earnings Insights
  Kymera Therapeutics (NASDAQ:KYMR) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022
  
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.